You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Authors

  • Anna K Maloney Quinnipiac University Frank H Netter MD School of Medicine, North Haven, Connecticut, USADepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Anita Giobbie-Hurder Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Nikita Katukota Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Miklos C Fogarasi Quinnipiac University Frank H Netter MD School of Medicine, North Haven, Connecticut, USA PubMed articlesGoogle scholar articles
  • Patrick A Ott Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • F Stephen Hodi Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Tamara A Sussman Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Ann W Silk Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Rizwan Haq Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • David Liu Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USADepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Megan Insco Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Elizabeth I Buchbinder Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles

Citation

Maloney AK, Giobbie-Hurder A, Katukota N, et al
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
Journal for ImmunoTherapy of Cancer 2024;12:e009061. doi: 10.1136/jitc-2024-009061
Online issue publication 
August 28, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.